📣 VC round data is live. Check it out!
- Public Comps
- Recursion Pharmaceuticals
Recursion Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Recursion Pharmaceuticals and similar public comparables like Vericel, Inhibrx Biosciences, Galapagos, ANI Pharmaceuticals and more.
Recursion Pharmaceuticals Overview
About Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Founded
2016
HQ

Employees
800
Website
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialRecursion Pharmaceuticals Financials
Recursion Pharmaceuticals reported last 12-month revenue of $75M and negative EBITDA of ($562M).
In the same LTM period, Recursion Pharmaceuticals generated $7M in gross profit, ($562M) in EBITDA losses, and had net loss of ($601M).
Revenue (LTM)
Recursion Pharmaceuticals P&L
In the most recent fiscal year, Recursion Pharmaceuticals reported revenue of $74M and EBITDA of ($559M).
Recursion Pharmaceuticals is unprofitable as of last fiscal year, with gross margin of 4%, EBITDA margin of (753%), and net margin of (868%).
Financial data powered by Morningstar, Inc.
Recursion Pharmaceuticals Stock Performance
Recursion Pharmaceuticals has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Recursion Pharmaceuticals' stock price is $3.51.
Recursion Pharmaceuticals share price increased by 1.4% in the last 30 days, and decreased by 16.1% in the last year.
Recursion Pharmaceuticals has an EPS (earnings per share) of $-1.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 3.5% | 1.4% | -4.4% | -16.1% | $-1.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRecursion Pharmaceuticals Valuation Multiples
Recursion Pharmaceuticals trades at 16.1x EV/Revenue multiple, and (2.1x) EV/EBITDA.
EV / Revenue (LTM)
Recursion Pharmaceuticals Financial Valuation Multiples
As of May 5, 2026, Recursion Pharmaceuticals has market cap of $2B and EV of $1B.
Recursion Pharmaceuticals has a P/E ratio of (3.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Recursion Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Recursion Pharmaceuticals Margins & Growth Rates
In the most recent fiscal year, Recursion Pharmaceuticals reported gross margin of 4%, EBITDA margin of (753%), and net margin of (868%).
Recursion Pharmaceuticals Margins
Recursion Pharmaceuticals Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Recursion Pharmaceuticals Operational KPIs
Recursion Pharmaceuticals' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.8M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Recursion Pharmaceuticals Competitors
Recursion Pharmaceuticals competitors include Vericel, Inhibrx Biosciences, Galapagos, ANI Pharmaceuticals, Generate Biomedicines, Harmony Biosciences, Lotus Pharmaceutical, Granules India, Cohance Lifesciences and Amylyx Pharmaceuticals.
Most Recursion Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 6.6x | 6.2x | 61.5x | 23.8x | |||
| 1424.5x | 2166.4x | (14.8x) | — | |||
| (1.3x) | (1.9x) | (3.9x) | (8.5x) | |||
| 2.5x | 2.3x | 10.6x | 8.8x | |||
| 53.1x | 57.1x | (8.1x) | (7.2x) | |||
| 1.5x | 1.4x | 5.0x | 4.7x | |||
| 4.8x | 4.1x | 12.2x | 11.7x | |||
| 3.4x | 3.3x | 15.1x | 14.9x | |||
This data is available for Pro users. Sign up to see all Recursion Pharmaceuticals competitors and their valuation data. Start Free Trial | ||||||
Recursion Pharmaceuticals Funding History
Before going public, Recursion Pharmaceuticals raised $435M in total equity funding, across 7 rounds.
Last private valuation of Recursion Pharmaceuticals was $1B, after raising $239M in September 2020 from Leaps by Bayer.
Recursion Pharmaceuticals Funding Rounds
Recursion Pharmaceuticals M&A Activity
Recursion Pharmaceuticals has acquired 4 companies to date.
Last acquisition by Recursion Pharmaceuticals was on August 8th 2024. Recursion Pharmaceuticals acquired Exscientia for $688M (EV/Revenue multiple of ).
Latest Acquisitions by Recursion Pharmaceuticals
| Description | Exscientia is an Oxford-based precision medicine company integrating AI, machine learning, and wet-lab automation to design novel drug candidates. It has advanced seven molecules into clinical trials, including DSP-1181 for OCD and GTAEXS617 for solid tumors. Publicly traded on Nasdaq since 2021, Exscientia holds partnerships with Sanofi, Bristol Myers Squibb, and Merck KGaA. Founded in 2016, the firm operates design studios in the UK, U.S., and Japan, focusing on oncology, immunology, and neurology targets. | Cyclica was a Toronto-based AI drug discovery company acquired by Recursion Pharmaceuticals in 2021. Its MatchMaker suite employed biophysics simulations and graph neural networks to predict protein-ligand binding affinities for over 3 billion virtual compounds. The platform supported polypharmacology analysis for repurposing existing drugs and de novo design, serving clients like AstraZeneca and Pfizer in oncology and neurology programs. | Valence Discovery is a Montreal-based AI drug discovery company pioneering few-shot learning for molecular design. The platform generates novel compounds for hard-to-drug targets using structure-based and ligand-optimized models. Valence partners with pharma giants like Sanofi for multiparameter optimization pipelines. Founded in 2021, it raised $25 million in Series A funding. | Vium is a San Mateo, California-headquartered biotechnology firm founded in 2013 that advances preclinical research through digital biomarkers. Fully AAALAC accredited with commendation for the 3Rs principles, it serves biotech, pharmaceutical, academic, and drug discovery clients. The Digital Vivarium and Vium Cloud platforms employ computer vision, AI, machine learning, and sensors for non-invasive monitoring of physiological metrics and behaviors in animal studies, enhancing data accuracy and study reproducibility. |
| HQ Country | ||||
| HQ City | Oxford | Toronto | Montreal | San Francisco, CA |
| Deal Date | 8 Aug 2024 | 8 May 2023 | 8 Mar 2023 | 28 Jul 2020 |
| Valuation | $688M | $40M | $48M | $3M |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Recursion Pharmaceuticals acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Recursion Pharmaceuticals
| When was Recursion Pharmaceuticals founded? | Recursion Pharmaceuticals was founded in 2016. |
| Where is Recursion Pharmaceuticals headquartered? | Recursion Pharmaceuticals is headquartered in United States. |
| How many employees does Recursion Pharmaceuticals have? | As of today, Recursion Pharmaceuticals has over 800 employees. |
| Who is the CEO of Recursion Pharmaceuticals? | Recursion Pharmaceuticals' CEO is Najat Khan. |
| Is Recursion Pharmaceuticals publicly listed? | Yes, Recursion Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Recursion Pharmaceuticals? | Recursion Pharmaceuticals trades under RXRX ticker. |
| When did Recursion Pharmaceuticals go public? | Recursion Pharmaceuticals went public in 2021. |
| Who are competitors of Recursion Pharmaceuticals? | Recursion Pharmaceuticals main competitors include Vericel, Inhibrx Biosciences, Galapagos, ANI Pharmaceuticals, Generate Biomedicines, Harmony Biosciences, Lotus Pharmaceutical, Granules India, Cohance Lifesciences, Amylyx Pharmaceuticals. |
| What is the current market cap of Recursion Pharmaceuticals? | Recursion Pharmaceuticals' current market cap is $2B. |
| What is the current revenue of Recursion Pharmaceuticals? | Recursion Pharmaceuticals' last 12 months revenue is $75M. |
| What is the current revenue growth of Recursion Pharmaceuticals? | Recursion Pharmaceuticals revenue growth (NTM/LTM) is 32%. |
| What is the current EV/Revenue multiple of Recursion Pharmaceuticals? | Current revenue multiple of Recursion Pharmaceuticals is 16.1x. |
| Is Recursion Pharmaceuticals profitable? | No, Recursion Pharmaceuticals is not profitable. |
| What is the current EBITDA of Recursion Pharmaceuticals? | Recursion Pharmaceuticals has negative EBITDA and is not profitable. |
| What is Recursion Pharmaceuticals' EBITDA margin? | Recursion Pharmaceuticals' last 12 months EBITDA margin is (754%). |
| What is the current EV/EBITDA multiple of Recursion Pharmaceuticals? | Current EBITDA multiple of Recursion Pharmaceuticals is (2.1x). |
| What is the current FCF of Recursion Pharmaceuticals? | Recursion Pharmaceuticals' last 12 months FCF is ($298M). |
| What is Recursion Pharmaceuticals' FCF margin? | Recursion Pharmaceuticals' last 12 months FCF margin is (399%). |
| What is the current EV/FCF multiple of Recursion Pharmaceuticals? | Current FCF multiple of Recursion Pharmaceuticals is (4.0x). |
| How many companies Recursion Pharmaceuticals has acquired to date? | As of May 2026, Recursion Pharmaceuticals has acquired 4 companies. |
| What was the largest acquisition by Recursion Pharmaceuticals? | $688M acquisition of Exscientia on 8th August 2024 was the largest M&A Recursion Pharmaceuticals has done to date. |
| What companies Recursion Pharmaceuticals acquired? | Recursion Pharmaceuticals acquired Exscientia, Valence Discovery, Cyclica, and Vium. |
| In how many companies Recursion Pharmaceuticals has invested to date? | Recursion Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Recursion Pharmaceuticals
Lists including Recursion Pharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


